公开(公告)号：US08216789B2

公开(公告)日：2012-07-10

申请号：US12394922

申请日：2009-02-27

申请人： Mary L. Disis ,  Vivian Goodell ,  Hailing Lu

发明人： Mary L. Disis ,  Vivian Goodell ,  Hailing Lu

IPC分类号： G01N33/53

CPC分类号： G01N33/57407 ,  G01N33/57473 ,  G01N2333/4725 ,  G01N2333/4739 ,  G01N2333/4745 ,  G01N2333/4748 ,  G01N2333/485

摘要： The invention provides a method for detection of a malignancy in a specimen of bodily fluid. The method comprises contacting the specimen with at least two antigens selected from the group consisting of p53, IGFBP2, Topo2α, cathepsin D, cyclin B, cyclin D1, MUC1, HER-2/neu and CEA. The method further comprises incubating the specimen and the antigen for a duration and under conditions that are sufficient for the formation of immunocomplexes; and detecting the presence or absence of immunocomplex formation between the antigens and antibodies specific for the antigens in the specimen, thereby determining the presence or absence of the malignancy. Also provided is a method for monitoring the effectiveness of cancer therapy related to a malignancy in a warm-blooded animal, a method for distinguishing between Stage I and Stage II colorectal cancer in a specimen of bodily fluid.

摘要翻译： 本发明提供一种用于检测体液中的恶性肿瘤的方法。 该方法包括使样品与选自p53，IGFBP2，Topo2α，组织蛋白酶D，细胞周期蛋白B，细胞周期蛋白D1，MUC1，HER-2 / neu和CEA的至少两种抗原接触。 该方法还包括在足以形成免疫复合物的条件下温育样品和抗原一段时间; 并检测抗原与样品中抗原特异性抗体之间存在或不存在免疫复合物形成，从而确定恶性肿瘤的存在或不存在。 还提供了用于监测与温血动物相关的恶性肿瘤的癌症治疗的有效性的方法，用于区分体液样本中的I期和II期结肠直肠癌的方法。

公开(公告)号：US20110318751A1

公开(公告)日：2011-12-29

申请号：US13163326

申请日：2011-06-17

申请人： Yoko MULLEN ,  Masato Mitsuhashi ,  Keiko Omori

发明人： Yoko MULLEN ,  Masato Mitsuhashi ,  Keiko Omori

IPC分类号： C12Q1/68 ,  G01N33/566 ,  C12N5/071

CPC分类号： C12Q1/6883 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/507 ,  G01N2333/4748 ,  G01N2333/525

摘要： p53-upregulated modulator of apoptosis (PUMA) is a biomarker associated with islet cell health. If PUMA is low, islet cells are typically healthy. If PUMA is high, islet cells are typically unhealthy or dying. PUMA may be measured by either measuring its nucleic or amino acid. PUMA mRNA may be induced by TNF-α stimulation in a time- and dose-dependent manner and β cell apoptosis is induced through a mitochondrial pathway. TNF-α significantly inhibited glucose-induced preproinsulin precursor mRNA synthesis. Such β cell stress signaling in human islets indicates overall state of islet health and, ultimately, the risk of onset and/or degree of severity of both type 1 and type 2 diabetes mellitus.

摘要翻译： p53上调凋亡调节剂（PUMA）是与胰岛细胞健康相关的生物标志物。 如果PUMA低，胰岛细胞通常是健康的。 如果PUMA高，胰岛细胞通常不健康或死亡。 PUMA可以通过测量其核酸或氨基酸来测量。 PUMA mRNA可能以时间和剂量依赖性方式诱导TNF-α刺激， 通过线粒体途径诱导细胞凋亡。 TNF-α显着抑制葡萄糖诱导的前胰岛素前体mRNA合成。 这样的 人胰岛中的细胞应激信号表示胰岛健康的总体状态，最终表明1型和2型糖尿病的发病风险和/或严重程度。

公开(公告)号：US08062887B2

公开(公告)日：2011-11-22

申请号：US11910313

申请日：2006-03-31

申请人： Kazuyasu Sakaguchi ,  Yoshiro Chuman ,  Yasuo Akebiyama ,  Miho Matsukizono ,  Maki Watanabe ,  Junichi Tsutsumi

发明人： Kazuyasu Sakaguchi ,  Yoshiro Chuman ,  Yasuo Akebiyama ,  Miho Matsukizono ,  Maki Watanabe ,  Junichi Tsutsumi

IPC分类号： C12N5/12 ,  C07K16/18

CPC分类号： C07K16/18 ,  C07K7/06 ,  C07K7/08 ,  G01N33/5748 ,  G01N2333/4748

摘要： The present invention provides a monoclonal antibody recognizing modification after translation of p53 in a manner specific to a modification site, an antibody microarray comprising the antibody immobilized on a substrate, etc. Disclosed is a monoclonal antibody which reacts specifically with a peptide consisting of an amino acid sequence of at least 6 consecutive amino acids containing a predetermined amino acid residue of the amino acid sequence represented by SEQ ID NO: 1, wherein the amino acid residue is phosphorylated or acetylated, or with a peptide having one to several arbitrary amino acids added to the above peptide, but does not react with the above peptide which is not phosphorylated or acetylated.

摘要翻译： 本发明提供了以对修饰位点特异性的方式翻译p53后的单克隆抗体，包含固定在底物上的抗体的抗体微阵列等。公开了与由氨基组成的肽特异性反应的单克隆抗体 含有由SEQ ID NO：1表示的氨基酸序列的预定氨基酸残基的至少6个连续氨基酸的酸序列，其中所述氨基酸残基被磷酸化或乙酰化，或者与具有一至几个任意氨基酸的肽相加 但不与未被磷酸化或乙酰化的上述肽反应。

公开(公告)号：US07985556B2

公开(公告)日：2011-07-26

申请号：US12063381

申请日：2006-08-09

申请人： Akira Nakagawara ,  Toshinori Ozaki

发明人： Akira Nakagawara ,  Toshinori Ozaki

IPC分类号： G01N33/53 ,  G01N33/567

CPC分类号： G01N33/574 ,  G01N33/5011 ,  G01N33/6896 ,  G01N2333/4748 ,  G01N2500/02 ,  G01N2510/00

摘要： Screening methods for determining pro-apoptotic compounds or anti-apoptotic compounds comprise measuring the interaction between p53 and NEDL1 in the presence and in the absence of a test compound, and comparing the strength of interaction between p53 and NEDL1 in the presence and in the absence of the test compound.

摘要翻译： 用于测定促凋亡化合物或抗凋亡化合物的筛选方法包括在存在和不存在测试化合物的情况下测量p53和NEDL1之间的相互作用，并且比较p53和NEDL1在存在和不存在下的相互作用强度 的试验化合物。

公开(公告)号：US20100189725A1

公开(公告)日：2010-07-29

申请号：US12667314

申请日：2008-07-03

申请人： Michelle Barton

发明人： Michelle Barton

IPC分类号： A61K31/713 ,  C12Q1/00 ,  C12Q1/68 ,  C07H21/02 ,  A61K31/7088 ,  A61K39/395 ,  A61K38/16 ,  A61K31/715 ,  A61P35/00 ,  A61P35/02

CPC分类号： C12Q1/25 ,  A61K31/7105 ,  C12N9/93 ,  C12N15/111 ,  C12N15/113 ,  C12N15/115 ,  C12N2320/12 ,  G01N33/5011 ,  G01N2333/4748 ,  G01N2333/9015 ,  G01N2500/04

摘要： Methods of screening for modulators of TRIM24 (also known as TIF1-ALPHA) expression and/or biological activity are described. In particular, methods of screening of screening for modulators of TRIM24 E3 ligase activity, and specifically an E3 ligase activity directed at p53 as the target polypeptide are also described. Modulators of TRIM24 expression and activity are provided and their use in treatment of cancer, particularly in breast, colon, prostate, renal cancers and in acute lymphoblastic leukaemia. Suitable modulators of TRIM24 expression include siRNA and shRNA and can be used in the treatment of cancer and for targeting cancer stem cells.

摘要翻译： 描述了对TRIM24（也称为TIF1-ALPHA）表达和/或生物活性的调节剂的筛选方法。 特别地，还描述了筛选TRIM24 E3连接酶活性的调节剂的筛选方法，特别是针对p53作为靶多肽的E3连接酶活性的方法。 提供TRIM24表达和活性的调节剂及其在治疗癌症中的用途，特别是在乳腺癌，结肠癌，前列腺癌，肾癌和急性淋巴细胞性白血病中的应用。 TRIM24表达的合适调节剂包括siRNA和shRNA，可用于治疗癌症和靶向癌症干细胞。

公开(公告)号：US20100056454A1

公开(公告)日：2010-03-04

申请号：US12617653

申请日：2009-11-12

申请人： Andrei V. Gudkov

发明人： Andrei V. Gudkov

IPC分类号： A61K38/16 ,  G01N33/53 ,  C07K14/00

CPC分类号： A61K38/1841 ,  A61K31/355 ,  A61K31/568 ,  A61K31/661 ,  A61K38/164 ,  A61K38/18 ,  A61K38/19 ,  A61K45/06 ,  C07K14/255 ,  G01N33/502 ,  G01N2333/4703 ,  G01N2333/4748 ,  G01N2333/495 ,  G01N2500/00 ,  Y02A50/481 ,  A61K2300/00

摘要： The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-κB activity. The modulators may be used, for example, in the treatment of NF-κB-mediated diseases, conditions, and injuries.

摘要翻译： 公开了凋亡调节剂的使用和筛选。 调节剂可以是例如NF-κB活性的调节剂。 调节剂可用于例如治疗NF-κB介导的疾病，病症和损伤。

公开(公告)号：US20060275255A1

公开(公告)日：2006-12-07

申请号：US11421918

申请日：2006-06-02

申请人： Andrei Gudkov

发明人： Andrei Gudkov

IPC分类号： A61K38/19 ,  A61K35/74 ,  G01N33/574 ,  G01N33/554

CPC分类号： A61K38/1841 ,  A61K31/355 ,  A61K31/568 ,  A61K31/661 ,  A61K38/164 ,  A61K38/18 ,  A61K38/19 ,  A61K45/06 ,  C07K14/255 ,  G01N33/502 ,  G01N2333/4703 ,  G01N2333/4748 ,  G01N2333/495 ,  G01N2500/00 ,  Y02A50/481 ,  A61K2300/00

摘要： The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-κB activity. The modulators may be used, for example, in the treatment of NF-κB-mediated diseases, conditions, and injuries.

摘要翻译： 公开了凋亡调节剂的使用和筛选。 调节剂可以是例如NF-κB活性的调节剂。 调节剂可用于例如治疗NF-κB介导的疾病，病症和损伤。

公开(公告)号：US20240124565A1

公开(公告)日：2024-04-18

申请号：US18475473

申请日：2023-09-27

申请人： Diadem SpA

发明人： Maurizio Memo ,  Daniela Letizia Uberti

IPC分类号： C07K16/18 ,  C07K16/32 ,  G01N33/68

CPC分类号： C07K16/18 ,  C07K16/32 ,  G01N33/6896 ,  C07K2317/34 ,  G01N2333/4748 ,  G01N2800/2821 ,  G01N2800/56 ,  G01N2800/7042

摘要： The invention relates to an anti-human p53 antibody suitable for specifically binding a linear epitope which is exposed only in a conformationally altered isoform of the characteristic p53 protein of patients with Alzheimer's disease or prone to develop Alzheimer's disease or cognitive impairment during ageing. Methods and diagnostic and prognostic kits are also described.

公开(公告)号：US20230266331A1

公开(公告)日：2023-08-24

申请号：US18005568

申请日：2021-07-14

申请人： ONCIMMUNE LIMITED

发明人： Andrea MURRAY ,  Jared ALLEN ,  Philip GUNNING ,  Isabel MACDONALD ,  Celine PARSY-KOWALSKA

IPC分类号： G01N33/574

CPC分类号： G01N33/57488 ,  G01N33/57423 ,  G01N2333/4748 ,  G01N2800/52

摘要： The present invention relates generally to the field of antibody detection, and in particular relates to methods involving the detection of autoantibodies relating to lung cancer in a sample comprising patient bodily fluid. In particular, the present invention relates to a method of detecting lung cancer in a mammalian subject by detecting three or more autoantibodies in a test sample, wherein three of the autoantibodies are immunologically specific for the tumour marker antigens p53, SSX1, and either p62 or KOC. The invention also relates to in vitro methods of determining an autoantibody profile, methods of diagnosing and treating lung cancer, methods of predicting response to a lung cancer treatment, use of a panel of three or more tumour marker antigens for the detection of lung cancer, and kits for the detection of autoantibodies.

公开(公告)号：US11650206B2

公开(公告)日：2023-05-16

申请号：US16900194

申请日：2020-06-12

申请人： ALBERT EINSTEIN COLLEGE OF MEDICINE, INC.

发明人： Harry Ostrer ,  Johnny C. Loke ,  Alexander Pearlman

IPC分类号： G01N33/574 ,  C12Q1/6886

CPC分类号： G01N33/57496 ,  C12Q1/6886 ,  G01N33/57415 ,  G01N33/57449 ,  G01N33/57484 ,  C12Q2600/156 ,  G01N2333/4703 ,  G01N2333/4748 ,  G01N2333/9108 ,  G01N2440/14 ,  G01N2800/50

摘要： Heritable mutations in the BRCA1 and BRCA2 and other genes in the DNA double-strand break (DSB) repair pathway increase risk of breast, ovarian and other cancers. In response to DNA breaks, the proteins encoded by these genes bind to each other and are transported into the nucleus to form nuclear foci and initiate homologous recombination. Flow cytometry-based functional variant analyses (FVAs) were developed to determine whether variants in BRCA1 or other DSB repair genes disrupted the binding of BRCA1 to its protein partners, the phosphorylation of p53 or the transport of the BRCA1 complex to the nucleus in response to DNA damage. Each of these assays distinguished high-risk BRCA1 mutations from low-risk BRCA1 controls. Mutations in other DSB repair pathway genes produced molecular phenocopies with these assays. FVA assays may represent an adjunct to sequencing for categorizing VUS or may represent a stand-alone measure for assessing breast cancer risk.